Immunotherapy before surgery shows promise for oral cancer
NCT ID NCT07514767
First seen Apr 09, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study tests whether giving the immunotherapy drug nivolumab before surgery can shrink advanced oral cancer tumors. About 60 adults with resectable oral squamous cell carcinoma will receive nivolumab, then have surgery. Researchers will also look for biomarkers in lymph nodes that predict response. The goal is to improve outcomes and understand who benefits most.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL SQUAMOUS CELL CARCINOMA (OSCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karolinska University Hospital, Head-, neck-, lung- and skin cancer, Theme Cancer
Stockholm, Sweden
Contact
Conditions
Explore the condition pages connected to this study.